Search results
Showing 16 to 30 of 80 results for vitamin d
ID NG14/09 Question Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation...
Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)
This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.
What is the best way of monitoring the local system for distributing vitamin D supplements?
What is the best way of monitoring the local system for distributing vitamin D supplements? Any explanatory notes(if applicable) The...
multiagency approach to improving awareness, availability and uptake of vitamin D supplements best be established, improved and...
supplements:- Should people with coeliac disease be offered calcium and vitamin D supplements for a specific time period soon after...
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
NG191/19 Question What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?...
Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?
Recommendation ID CG186/5 Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.
PH56/2 Question How cost effective are preventive approaches to vitamin D deficiency among all at-risk groups, compared with the cost of...
Question How effective and cost effective are interventions to increase vitamin D access, uptake, adherence or status among identified...